{"id":"oxytocin-versus-oxytocin-ergometrine","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Coronary vasospasm (ergometrine-related)"},{"rate":null,"effect":"Uterine tetany"}]},"_chembl":{"chemblId":"CHEMBL4303358","moleculeType":"Small molecule","molecularWeight":"1007.21"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxytocin binds to oxytocin receptors on uterine smooth muscle, triggering contractions essential for labor progression and postpartum hemostasis. Ergometrine (methylergonovine) provides additional vasoconstriction and sustained uterine contraction through alpha-adrenergic and serotonergic mechanisms, making the combination more effective at preventing postpartum hemorrhage than oxytocin alone.","oneSentence":"Oxytocin is a hormone that stimulates uterine contractions and milk letdown, while the oxytocin-ergometrine combination adds ergot alkaloid activity to enhance and sustain uterine contractions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:41:44.320Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention and treatment of postpartum hemorrhage"},{"name":"Augmentation of labor"}]},"trialDetails":[{"nctId":"NCT07390864","phase":"NA","title":"Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy","status":"RECRUITING","sponsor":"Cairo University","startDate":"2026-01-18","conditions":"Myoma;Uterus","enrollment":40},{"nctId":"NCT03390010","phase":"PHASE1","title":"Misoprostol Versus Active Management of Labour in CS","status":"COMPLETED","sponsor":"Aljazeera Hospital","startDate":"2017-12-28","conditions":"Cesarean Section","enrollment":300},{"nctId":"NCT02044549","phase":"PHASE4","title":"Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section","status":"COMPLETED","sponsor":"Cairo University","startDate":"2014-06","conditions":"Postpartum Hemorrhage, Blood Loss","enrollment":300},{"nctId":"NCT03578263","phase":"NA","title":"Carbetocin Versus Oxytocin and Ergometrine for the Prevention of Postpartum Hemorrhage","status":"COMPLETED","sponsor":"Aswan University Hospital","startDate":"2018-04-01","conditions":"Cesarean Section Complications","enrollment":220},{"nctId":"NCT03693599","phase":"PHASE4","title":"Carbetocin Versus Syntometrine in Obese Women Undergoing Elective Cesarean","status":"COMPLETED","sponsor":"Cairo University","startDate":"2018-10-01","conditions":"Post Partum Hemorrhage","enrollment":1200},{"nctId":"NCT01549223","phase":"PHASE4","title":"Oxytocin And Uterotonic Agent Use For Cesarean Delivery","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-04","conditions":"Uterine Atony, Hypotension","enrollment":60},{"nctId":"NCT02306733","phase":"PHASE3","title":"Ergometrine Versus Oxytocin in the Management of Atonic Post-partum Haemorrhage (PPH) in Women Delivered Vaginally","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2014-11","conditions":"Post Partum Hemorrhage","enrollment":200},{"nctId":"NCT02410759","phase":"PHASE3","title":"Carbetocin Versus Ergometrine in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2015-04","conditions":"Post Partum Hemorrhage","enrollment":200},{"nctId":"NCT02101567","phase":"PHASE4","title":"Carbetocin Versus Oxytocin and Ergometrine for the Prevention of Postpartum Haemorrhage Following Caesarean Section","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2014-05","conditions":"Bleeding, Anemia","enrollment":200},{"nctId":"NCT01236482","phase":"PHASE4","title":"Oxytocin in Cesarean Delivery","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2010-11","conditions":"Post Partum Hemorrhage","enrollment":80},{"nctId":"NCT00481533","phase":"NA","title":"Ergot and Oxytocin During Cesarean Delivery Following Failure to Progress in Labour","status":"COMPLETED","sponsor":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","startDate":"2005-06","conditions":"Blood Loss, Surgical","enrollment":47}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Oxytocin versus oxytocin-ergometrine","genericName":"Oxytocin versus oxytocin-ergometrine","companyName":"Hadassah Medical Organization","companyId":"hadassah-medical-organization","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxytocin is a hormone that stimulates uterine contractions and milk letdown, while the oxytocin-ergometrine combination adds ergot alkaloid activity to enhance and sustain uterine contractions. Used for Prevention and treatment of postpartum hemorrhage, Augmentation of labor.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}